[China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2013 Earnings Results and Schedules Conference Call for July 5, 2013 Fiscal Year 2013 Highlights: · Revenues from retail sales decreased to $40.7 million, down 38.4% from the prior period · Gross profit was $14.6 million, down 46.9% from the prior year · Net loss was $14.3 million · Diluted and basic loss]
[FORM 10-K þ For the fiscal year ended March 31, 2013 or o For the transition period from _______________________ to ___________________ 001-34711 CHINA JO-JO DRUGSTORES, INC . (Exact name of issuer as specified in its charter) Nevada 98-0557852 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Room 507-513, 5th Floor A Building, Meidu Plaza Gongshu District,] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang Jiuxin Investment] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-171849) of China Jo-Jo Drugstores, Inc. and subsidiaries of our report dated July 1, 2013 relating to the consolidated financial statements, which appear in this Form 10-K. New York, New York July 1, 2013 EX-23 3] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Lei Liu Chief Executive Officer July 1, 2013 EX-32.1 6 f10k2013ex32i_chinajojo.htm SECTION 906 CERTIFICATION BY] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Ming Zhao Ming Zhao Chief Financial Officer July 1, 2013 EX-32.2 7 f10k2013ex32ii_chinajojo.htm SECTION 906 CERTIFICATION BY]
[FORM 10-K þ For the fiscal year ended March 31, 2013 or o For the transition period from _______________________ to ___________________ 001-34711 CHINA JO-JO DRUGSTORES, INC . (Exact name of issuer as specified in its charter) Nevada 98-0557852 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Room 507-513, 5th Floor A Building, Meidu Plaza Gongshu District,] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang Jiuxin Investment] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-171849) of China Jo-Jo Drugstores, Inc. and subsidiaries of our report dated July 1, 2013 relating to the consolidated financial statements, which appear in this Form 10-K. New York, New York July 1, 2013 EX-23 3] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Lei Liu Chief Executive Officer July 1, 2013 EX-32.1 6 f10k2013ex32i_chinajojo.htm SECTION 906 CERTIFICATION BY] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Ming Zhao Ming Zhao Chief Financial Officer July 1, 2013 EX-32.2 7 f10k2013ex32ii_chinajojo.htm SECTION 906 CERTIFICATION BY]
[China Jo-Jo Drugstores, Inc. Receives Delisting Notice from NASDAQ HANGZHOU, China--(PR NEWS WIRE)--China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) (the “Company”), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced that on May 9, 2013, it was notified by The NASDAQ Stock Market LLC (“NASDAQ”), notifying it of its failure to maintain a minimum closing bid]
[China Jo-Jo Drugstores, Inc. Receives Delisting Notice from NASDAQ HANGZHOU, China--(PR NEWS WIRE)--China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) (the “Company”), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced that on May 9, 2013, it was notified by The NASDAQ Stock Market LLC (“NASDAQ”), notifying it of its failure to maintain a minimum closing bid]
[FORM 8-K CURRENT REPORT Date of report (Date of earliest event reported): April 1, 2013 (March 29, 2013) CHINA JO-JO DRUGSTORES, INC. Nevada 001-34711 98-0557852 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) Room 507-513, 5th Floor, A Building, Meidu Plaza Gongshu District, Hangzhou, Zhejiang Province People’s Republic of China (Zip Code) +86 (571) 88077078]
[DEFINITIVE SCHEDULE 14A INFORMATION x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ CHINA JO-JO DRUGSTORES, INC. Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to]
[DEFINITIVE SCHEDULE 14A INFORMATION x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ CHINA JO-JO DRUGSTORES, INC. Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to]
[DEFINITIVE SCHEDULE 14A INFORMATION x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ CHINA JO-JO DRUGSTORES, INC. Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to]
[CHINA JO-JO DRUGSTORES REPORTS THIRD QUARTER EARNINGS RESULTS HANGZHOU, China--(BUSINESS WIRE)--China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), (the “Company”), a retail and wholesale distributor of pharmaceutical and other healthcare products in Zhejiang and Shanghai, today reported earnings results for the third quarter of fiscal 2013 ended December 31, 2012. The Company will hold its earnings call on Tuesday, February 19, 2013,]
